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Background:  Plasmodium  vivax  circumsporozoite  (PvCS)  protein  is  a  major  sporozoite  surface  antigen
involved  in parasite  invasion  of  hepatocytes  and is  currently  being  considered  as  vaccine  candidate.  PvCS
contains  a  dimorphic  central  repetitive  fragment  ﬂanked  by  conserved  regions  that  contain  functional
domains.
Methods:  We  have  developed  a  chimeric  137-mer  synthetic  polypeptide  (PvCS-NRC)  that  includes  the
conserved  region  I and  region  II-plus  and the  two  natural  repeat  variants  known  as  VK210  and  VK247.
The  antigenicity  of  PvCS-NRC  was  tested  using  human  sera  from  PNG  and  Colombia  endemic  areas  and  its
immunogenicity  was  conﬁrmed  in mice  with  different  genetic  backgrounds,  the  polypeptide  formulated
either  in Alum  or GLA-SE  adjuvants  was  assessed  in  inbred  C3H,  CB6F1  and  outbred  ICR mice,  whereas  a
formulation  in  Montanide  ISA51  was  tested  in C3H  mice.
Results: Antigenicity  studies  indicated  that the  chimeric  peptide  is  recognized  by a high proportion
(60–70%)  of  residents  of malaria-endemic  areas.  Peptides  formulated  with  either  GLA-SE or  Montanide
ISA51  adjuvants  induced  stronger  antibody  responses  as  compared  with  the Alum  formulation.  Sera
from  immunized  mice  as well  as  antigen-speciﬁc  afﬁnity  puriﬁed  human  IgG antibodies  reacted  with
sporozoite  preparations  in  immunoﬂuorescence  and  Western  blot  assays,  and displayed  strong  in  vitro
inhibition  of  sporozoite  invasion  (ISI)  into  hepatoma  cells.
Conclusions: The  polypeptide  was  recognized  at high  prevalence  when  tested  against  naturally  induced
human  antibodies  and  was  able  to  induce  signiﬁcant  immunogenicity  in mice.  Additionally,  speciﬁc
antibodies  were  able  to recognize  sporozoites  and  were  able  to block  sporozoite  invasion  in vitro.  Further
evaluation  of  this  chimeric  protein  construct  in  preclinical  phase  e.g. in  Aotus  monkeys  in  order  to  assess
the  humoral  and  cellular  immune  responses  as  well  as  protective  efﬁcacy  against  parasite  challenge  of
st  be
 2013the  vaccine  candidate  mu
©
. IntroductionPlasmodium vivax, the second most important Plasmodium
pecies in terms of epidemiological signiﬁcance, causes ∼70–80
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million clinical cases of malaria annually with 2.85 billion people
living at risk of infection [1]. Although this parasite has been con-
sidered benign, during the last decade lethal P. vivax malaria cases
have been documented [2,3] and chloroquine-resistant strains have
recently emerged [4,5]. Furthermore, this parasite species produce
hypnozoites forms that upon periodic reactivation induce clinical
relapses, even in individuals who have emigrated from endemic
regions.
During the last 2–3 decades, signiﬁcant efforts have been
Open access under CC BY-NC-ND license.invested in the development of Plasmodium falciparum subunit
vaccines [6–8] and currently the RTS,S construct based on the P.
falciparum circumsporozoite (CS) protein is the most advanced
malaria vaccine candidate [9]. The CS protein is abundantly
 license.
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xpressed on the sporozoite (spz) surface of all Plasmodium species.
t is one of the antigens that is predominantly recognized by sera of
ndividuals rendered immune after vaccination with irradiated spz
10], and by individuals from endemic areas who have developed
linical immunity [11,12]. In P. vivax, the central repeat domain
90–261 aa) is composed of 19 blocks of 9 amino acids each, with
wo allelic forms circulating in nature: the VK210 or common type
GDRADGQPA) [13] and the VK247 or variant type (ANGAGNQPG)
14]. Flanking regions contain small stretches of highly conserved
equences designated as region I (85–89 aa) and region II-plus
338–355 aa) that represent ligand domains for invasion of hep-
tocytes [15,16].
It  has been shown that the CS protein is proteolytically cleaved at
egion I (RI) [17,18], and that this processing is required for parasite
nvasion. Antibodies to RI as well as those against the repeat region
re able to block the cleavage process [15,17], thus, an effective
accine targeting the CS protein must be able to elicit antibodies
peciﬁc to the RI as well as to the two repeats variants regions.
During  the last decade, the P. vivax CS (PvCS) has been exten-
ively characterized [19–21], and both preclinical studies and Phase
 clinical trials using long synthetic peptides (LSP) corresponding to
he N, R and C regions of the protein have indicated its potential as
 vaccine candidate [22–25]. In addition, a recombinant chimeric
vCS construct containing both the VK210 and the VK247 repeat
ariants was recently produced in Escherichia coli and its immuno-
enicity tested in mice. Different formulations of the construct were
ound to elicit antibodies that agglutinated live sporozoites [26,27].
Herein, we describe studies on novel formulations of the
himeric PvCS-NRC synthetic vaccine containing critical epitopes
n a single construct joined together by the non-immunogenic
odiﬁed diethylene glycol linker (DEG), selection of fragments
as based on previous studies on the characterization of the
vCS protein (identiﬁcation of B, CD4+, CD8+ epitopes) and on the
mmunogenicity of a pools of individuals peptides tested in mice,
onkeys and humans [19–25].
. Materials and methods
.1.  Vaccine
The polypeptide PvCS-NRC was synthesized using solid-phase
uorenylmethoxycarbonyl (F-moc) chemistry [28]. Pseudoproline
oxazolidine) dipeptides were introduced at critical points in the C-
erminal region and DEG (Merck Chemicals Ltd., Nottingham, UK)
as inserted between the three fragments RI+VK210, RI+VK247
nd C (Fig. 1A). Pre-puriﬁed tertiary-butylthiolated precursors
ere oxidized and folded in solution accordingly [29]. The result-
ng construct was  HPLC-puriﬁed and the purity (>85%) conﬁrmed
y analytic C18 HPLC (Fig. 1B) and mass spectrometry (Fig. 1C)
MALDI-TOF; Applied Biosystem). A polypeptide model was  built
sing the INSIGHT II program (Accelrys, San Diego) [30] (Fig. 1D).
Additionally,  seven 20-aa long synthetic peptides identiﬁed as
-cell and T-helper (Th) epitopes located in the N-terminal (p8, p9
nd p40) and central repeat (p10, p11, p32 and p43) regions of the
. vivax CS protein, and a LSP representing the carboxyl-terminal
egion (301–372 aa) designated as C-peptide, were synthesized and
sed to characterize antibody responses.
.2. Human sera
Human  serum samples of adults from malaria-endemic areas
f Colombia and Papua New Guinea (PNG) as well as from a
on-endemic area (Switzerland) were used to assess peptide anti-
enicity. PNG sera (n = 42) were collected in a cross-sectional study
arried out in a highly malaria-endemic region of Maprik District,
ast Sepik Province [31]. The Colombian samples (n = 32) were
btained in the Buenaventura region where P. vivax is endemic1 (2013) 4923– 4930
with  a constant low level of transmission [32]. Ethical clearance
was obtained from the PNG Medical Research Advisory Committee
as well as from the IRB of the Malaria Vaccine and Drug Develop-
ment Center (MVDC) in Colombia. Negative control samples were
obtained from Swiss adult donors with no malaria history and no
previous travel to malaria-endemic areas and used as control in
ELISA and IFA test.
2.3.  Immunogenicity studies in mice
Groups of ﬁve mice corresponding to two syngeneic strains
(C3H, CB6F1) and a group of seven outbred mice (ICR) were
injected with PvCS-NRC formulated in alhydrogel (1 mg/mouse)
and GLA-SE (20 g/mouse) [33,34], respectively, whereas a Mon-
tanide ISA51 (Seppic Inc., Paris, France) formulation was assessed in
C3H mice according to manufacturer’s recommendations. All mice
were injected subcutaneously with 20 g of peptide in 50 L vol-
ume at the base of the tail on days 0, 20 and 40. Animals care was
performed in accordance with institutional guidelines.
2.4. Humoral immune response
Antibody responses to PvCS-NRC as well as to the other peptides
in mice and human were measured by ELISA; PvCS-NRC was used at
1  g/mL, whereas the constituent peptides were used at 5 g/mL,
and the ELISA performed as described previously [19]. Additionally,
parasite recognition by anti-peptide antibodies was  determined by
IFAT using P. vivax sporozoites as described previously [35]. Cut-
off points for ELISA were calculated as three SD above the mean
absorbance value at 405 nm of normal mouse sera or from healthy
volunteers who had never been exposed to malaria. IFAT antibody
titers were determined as the reciprocal of the end-point dilution
that showed positive ﬂuorescence [23].
2.5. Reactivity of afﬁnity-puriﬁed human antibodies
Reactivity of puriﬁed human antibodies with the polypeptide as
well as the different constituents was determined by ELISA com-
petition assay, using PvCS-NRC (1 g/mL) as the antigen substrate.
Human IgG speciﬁc to PvCS-NRC were puriﬁed from pooled sera
(50 mL) obtained from adults living in malaria-endemic areas of
PNG as described previously [36]. The afﬁnity-puriﬁed antibodies
to PvCS-NRC were incubated 30 min  at room temperature together
with the constituent polypeptides (RI, VK210, VK247 or C) prior
to adding to the peptide-coated ELISA plates. Reactivity of the
adsorbed antibody preparations was  then determined as described
elsewhere (Section 2.6).
2.6.  Western blot analysis
Protein  extracts from lysed P. vivax sporozoites were separated
on 12% SDS-polyacrylamide gel and electro-transferred to nitrocel-
lulose (0.2 mm,  Whatman Schleicher + Schuell, Florham Park, NJ)
under cooling conditions overnight at 30 V. The membrane was
blocked at room temperature, incubated with the primary anti-
body solution (puriﬁed IgG or sera from immunized mice), washed
and incubated with an alkaline phosphatase-conjugated goat anti-
mouse or anti-human IgG (1:1000, Sigma) [37]. Bound antibodies
were visualized using BSIP/NBT substrate.
2.7. Inhibition of sporozoite invasion (ISI) assayAfﬁnity-puriﬁed human IgG antibodies speciﬁc to PvCS-NRC as
well as sera of immunized mice were tested for the capacity to
inhibit P. vivax sporozoite invasion of HepG2-A16 hepatoma-cells
in vitro as described previously [22].
N. Céspedes et al. / Vaccine 31 (2013) 4923– 4930 4925
Fig. 1. PvCS-NRC structure and production. (A) Schematic representation of the PvCS and localization of epitopes included in the PvCS-NRC construct. DEG: diethylene
glycol derivative. Sequence: KAEPKNPREN KLKQPGDRAD GGPAGDRADG QPA-DEG-KAEPKNPREN KLKQPGENGA GDQPGANGAG NQPG-DEG-NEGANAPNEK SVKEYLDKVR
ATVGTEWTPC SVTCGVGVRV RRRVNAANKK PEDLTLNDLE TDVCTMDKCA. (B) MALDI TOF mass spectrum of PvCS-NRC. After size exclusion chromatography pre-puriﬁed
(G75) samples were subject to folding of Cys(StBu) induced by a 100-fold molar excess of cysteine at 37 ◦C, pH 7.2, for 24 h. The main impurity corresponds to an incomplete
oxidation of one 1 Stbu (m/z: 15145). The peak at m/z 15278 corresponds to the sinapinic acid addition product generated by the laser treatment of the sample during the
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cass  spectrometry analysis. (C) HPLC chromatogram of PvCS-NRC. (D) Structural m
red)  and DEG cross-linkers (orange) is unfolded [49] while the C-terminal half form
omain from P. falciparum (pdb code 3VDJ) [50]. The RII region is shown in blue.
.8. Statistical analysis
Main  experimental comparisons involved analysis of differ-
nces between adjuvants and strains of mice. Antibody titers
ere compared among adjuvants and strains of mice and a
escriptive analysis was performed to evaluate trends in humoral
mmune responses within each group of mice. Additionally, the
ann–Whitney test was performed with OD data obtained after thehird immunization to compare the antibody response of different
roups of adjuvants, and the Kruskal–Wallis test was  used to com-
are different strains of mice. Non-parametric p values ≤0.05 were
onsidered statistically signiﬁcant. Finally, the capacity to inhibitf peptide PvCS-NRC. The N-terminal half of the peptide that includes two RI regions
ular structure that was modeled by using the crystal structure of the homologous
P.  vivax sporozoite invasion of HepG2-A16 hepatoma-cells in vitro
was compared between adjuvants in the different strains of mice
using the Mann–Whitney test.
3. Results
3.1. Antigenic recognitionTable  1 shows the prevalence of seropositive reactivity using
serum samples from PNG and Colombia endemic areas, tested
against PvCS-NRC and other CS fragments. In general, all polypep-
tides used in this study were more frequently recognized by PNG
4926 N. Céspedes et al. / Vaccine 3
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sera than by Colombian sera. More than 65% of adult donors from
PNG and 58% Colombian adults recognized the PvCS-NRC antigen.
Additionally, most of the polypeptide fragments were also recog-
nized by up to 76% of PNG samples and up to 44% of Colombian
samples (Table 1). Peptides P9 and P40, containing the PvCS-RI
region, were the epitopes most frequently recognized by Colom-
bian sera (44%); whereas PNG sera were most reactive to P8 and P10
peptides (76%). The prevalence of antibodies speciﬁc for P11 and
P32 peptides corresponding to the two repeat variants (VK210 and
VK247, respectively) were also higher in PNG (>65%) with similar
frequency of recognition within the same region (Table 1). Finally,
the C-terminus was recognized by 59% and 30% of PNG and Colom-
bian sera, respectively.
3.2.  Reactivity of puriﬁed IgG antibodies
Reactivity and speciﬁcity of the afﬁnity-puriﬁed IgG were con-
ﬁrmed by ELISA and IFA tests. Antibodies showed reactivity to
PvCS-NRC by ELISA at dilutions to 0.1 g/mL, and recognized the
native protein on P. vivax sporozoites by IFAT at a concentration
of 16 g/mL. Moreover, anti-PvCS-NRC antibodies recognized each
of the individual constituent fragments by ELISA inhibition assay;
antibodies reacted mainly with RI and C-regions followed by both
VK210 and VK247 repeat regions (Fig. 2A). Finally, Western blot
analysis of speciﬁc anti-PvCS-NRC puriﬁed antibodies recognized
a double band at approximately 50 kDa typical of the CS protein
(Fig. 2B).
3.3.  Immunogenicity in mice
Antibody titers were determined in all inbred and outbred
immunized mice (Table 2). Stronger antibody titers were gener-
ally observed when the polypeptide was  formulated in GLA-SE and
Montanide ISA51 than in Alum (p = 0.0001). Moreover, antibody
responses were more consistent for the GLA-SE vaccine formula-
tion, while high variability in number of responders and antibody
titers was observed for mice inoculated with the Alum formula-
tion. Although differences in response to PvCS-NRC formulated in
GLA-SE or Alum were observed between the different strains of
mice (Table 2), no signiﬁcant differences were observed among the
two syngeneic (C3H, CB6F1) strains and the outbred (ICR) strain
(p = 0.220).
CB6F1 and ICR mouse strains showed higher ELISA antibody
titers, ranging from 6.5 × 105 to 5.9 × 106, when they were immu-
nized with the PvCS-NRC formulated in GLA-SE. In both cases
seroconversion was detected after the second immunization, with
boosting observed after the third immunization (Fig. 3). In the
case of C3H mice, ELISA titers were highly variable, ranging from
8.1 × 103 to 1.9 × 106, with the exception of one animal that
required three vaccine doses before seroconversion, all other mice
seroconverted after the second immunization. Regarding PvCS-
NRC-Alum formulations, most of the animals seroconverted with
the second immunization dose, yet others required the third dose to
seroconvert. The highest response was observed in the CB6F1 strain
of mice with ELISA titers ranging between 3.0 × 102 and 6.6 × 105,
whereas the lowest response was shown in ICR and C3H mouse
strains with ELISA titers ranging between 9.0 × 102 and 7.2 × 104,
and 3.0 × 102 and 8.1 × 103, respectively (Fig. 3).
Similar  to GLA-SE, the PvCS-NRC polypeptide formulated in
Montanide ISA 51 induced potent antibody responses in C3H mice
with average ELISA titers between 6.6 × 105 and 5.9 × 106 and all
mice seroconverted after the second immunization (Fig. 3).Antibodies  to PvCS-NRC recognized the entire polypeptide and
the individual peptide fragments, although some variability was
observed depending on the adjuvant or mouse strain used (Fig. 4A).
In general, the C-terminal fragment and the RI-containing peptide
N. Céspedes et al. / Vaccine 31 (2013) 4923– 4930 4927
Fig. 2. Antibodies reactivity. (A) ELISA competition assay using anti-human speciﬁc puriﬁed antibodies to PvCS-NRC. Human afﬁnity-puriﬁed antibodies to PvCS-NRC were
incubated together with the constituent polypeptides (RI, VK210, VK247 or C) at serial dilutions starting at 1 mg/mL and the reaction incubated for 30 min  at room temperature,
prior their addition to the ELISA peptide-coated plates. (B) Immunoblot assays: lysed P. vivax sporozoites electrophoresed under non-reducing conditions were probed with
afﬁnity-puriﬁed human -PvCS-NRC or antibodies produced in mice at 1:100 dilution. Relative size standards are indicated on the left in kDa. As negative control non-speciﬁc
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ouman puriﬁed antibodies from Swiss donors or sera of mice immunized with a P. f
n  Montanide were used. As a positive control a pool of serum samples from adults
P9) were the most frequently recognized, followed by the VK210
epeat. The VK247 repeat was recognized only by sera of mice
mmunized with PvCS-NRC formulated in GLA-SE.
All immunized mice recognized P. vivax sporozoites by IFA,
egardless of the adjuvant used, albeit at different antibody titers
Fig. 4B). Higher responses were observed in CB6F1 and ICR mice
mmunized with the GLA-SE formulation (IFA titers: 1:10,240),
ollowed by responses in sera of C3H mice immunized with the
ontanide ISA51 formulation (IFA titers: 1:5000), and then by sera
f CB6F1 mice immunized with Alum (IFA titer: 1:1280).
Finally, Western blot analysis of the anti-PvCS-NRC pool of
era corresponding to C3H mice immunized with Montanide, and
CR and CB6F1 mice with GLA-SE formulation or Alum formula-
ion recognized two bands at approximately 50 kDa and ∼15 kDa
Fig. 2B), while no response was observed with serum pool of
3H mice immunized with PvCS-NRC formulated in GLA-SE or
lum.
.4. Inhibition of sporozoite invasion (ISI) assay
Functional activity of speciﬁc PvCS-NRC-puriﬁed human anti-
odies and of whole antisera obtained after the third immunization
as tested in ISI assays to determine the capacity of anti-
eptide antibodies to inhibit P. vivax sporozoite invasion of human
epatoma-cells (HepG2À-16) in vitro. Human antibodies to the
ntire PvCS-NRC polypeptide resulted in inhibitory activity up
o 70%. Likewise, mouse sera produced strong inhibition (>65%),
lthough the strongest inhibition (>75%) was observed in sera of
ice immunized with PvCS-NRC formulated in GLA-SE. No sig-
iﬁcant differences were observed among the different adjuvant
roups (p = 0.08) (Fig. 4C).
able 2
mmunogenicity of PvCS-NRC formulated in different adjuvants in mice.
Adjuvant C3H Responders CB6F1 
GLA-SE 1.54 ± 0.91 5/5 2.26 ± 0.3
Alum  0.09 ± 0.05 3/5 0.36 ± 0.2
p  0.0061 0.0061 
ata represented as OD media. Mann–Whitney test was  performed with OD data obtained
f  adjuvants. p values ≤0.05 were considered signiﬁcant.rum erythrocytic antigen formulated in GLA-SE [46] and the homologous in P. vivax
nized with a mixture of PvCS LSP in a Phase 1b clinical trial were used [25].
4. Discussion
In the process of developing a pre-erythrocytic P. vivax vaccine
for human use, we have developed a chimeric LSP derived from the
P. vivax CS protein which includes an N-fragment-containing region
I; the two repeat variants found in nature (VK210 and VK247);
and the C fragment, all considered to play an important functional
roles in sporozoite invasion of hepatocytes [15,17]. It is encour-
aging that the chimeric polypeptide construct, named PvCS-NRC,
and its individual peptides, were widely recognized by sera of
individuals naturally exposed to malaria and additionally induced
signiﬁcant response in immunized mice. Of particular interest anti-
bodies elicited recognized the protein on sporozoites and blocked
sporozoite invasion in vitro.
All CS protein fragments studied were recognized by ELISA
when tested with sera collected from both PNG and Colombian
donors although, as expected each one was  recognized with differ-
ent frequencies, most likely due to the varying P. vivax endemicity
in the respective countries [38,39]. Although, in some cases the
response to individual peptides seem to be greater than the full
construct, especially for PNG samples, it is not possible to compare
the additive or synergistic response since the amount of antigen
used to test the PvCS-NRC and their corresponding antigens was
different. As previously shown [19], peptides corresponding to N-
terminal ﬂanking regions as well as to the repeat regions were
more frequently recognized by human sera than that correspond-
ing to the C-region. In fact, under natural conditions, the C-region
appears to be masked by the N-fragment of the protein, and there-
fore it may  be less exposed to the immune system [17]. However,
in previous studies we  have observed that even when peptides
containing nearly complete N and C regions when administered
Responders ICR Responders
4 5/5 2.66 ± 0.53 6/6
0 5/5 0.28 ± 0.18 5/6
0.001
 after the third immunization to compare the antibody response of different groups
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Fig. 3. Humoral response to PvCS-NRC peptide formulated in Alum, GLA-SE or Montanide, determined in (A) C3H mice, (B) CB6F1 mice and (C) ICR mice. (D) C3H with PvNRC
formulated in Montanide. Antibody titers are expressed in log10 of immune sera determined as the last dilution with an OD higher than that of the control serum + 3SD. The
i  imm
f  test s
s
i
a
g
h
d
f
t
o
tnduced  antibody responses were measured by ELISA ten days after second and third
rom  1:100 to 1: 1.7 × 107. Results were considered positive when absorbance of the
era  samples obtained from naïve mice were used as control sera at 1:200 dilution.
ndependently, the N-fragment is more immunogenic in monkeys
nd humans than the C-fragment, with the latter more immuno-
enic in mice [22]. This observation is a critical consideration for
uman use vaccines development.
Herein, although PvCS-NRC displayed varying immunogenicity
epending on the different vaccine formulations, reactivity of all
ormulations in both inbred and outbred mouse strains conﬁrms
he presence of multiple T-cell epitopes along the entire length
f PvCS-NRC. Regarding helper efﬁciency, C and RI regions were
he most frequently recognized by speciﬁc PvCS-NRC antibodies.unizations. ELISA was performed using threefold serial dilutions of the sera, starting
era was greater than or equal to the mean value of control sera + 3SD. Normal mice
The  lower immunogenicity of VK247 peptide is noteworthy; how-
ever we had also found that in endemic Colombian regions where
VK247 is the prevalent phenotype [40], antibodies to VK210 were
more frequent than those to VK247, probably indicating its greater
immunogenicity [41].
It  was  interesting to conﬁrm that puriﬁed human IgG speciﬁc
to the polypeptide recognized the individual epitopes comprised
in PvCS-NRC in ELISA, and were reactive to parasite in IFA and
Western blot. Even more meaningful was  the capacity displayed
by the speciﬁc anti-PvCS-NRC antibodies to inhibit sporozoite
N. Céspedes et al. / Vaccine 3
Fig. 4. Anti-PvNRC produced in mice. (A) Comparison of mice ELISA-antibody titers
to PvCS-NRC and to individual components. A pool of sera for each mice group was
used to determine the reactivity of anti-PvCS-NRC antibodies to VK210, VK247 P9
and C fragments. (B) IFAT proﬁles of sera from different mice strains immunized with
PvCS-NRC vaccine formulations. Antibody titers are expressed in log10 of immune
sera  determined as the last dilution that showed positive ﬂuorescence. (C) In vitro
inhibition sporozoite invasion. The HepG2-A16 cells were at a density of 8 × 104
cells/0.3 mL  of medium, 3 × 104 P. vivax sporozoites were used. A 100 g/mL puri-
ﬁed IgG antibodies or 1:20 dilution of sera from mice immunized were added to
each well. Percentages of inhibition are shown as the mean ± SD of duplicate wells.
Each experiment was performed twice with similar results. Percentage of inva-
sion inhibition was  calculated by the formula: ([mean schizont number of negative
control − mean schizont number of sample/mean schizont number of negative con-
trol] × 100). Negative control was normal mouse sera or Colombian normal human
sera  from naïve donors. Percentage of invasion inhibition was compared between
GLA-SE  and Alum adjuvants in the different strains of mice using the Mann–Whitney
test  p values ≤0.05 were considered signiﬁcant.1 (2013) 4923– 4930 4929
invasion in vitro. This might be associated with the signiﬁcant clin-
ical immunity observed in PNG [31]. Likewise, sera of immunized
mice were also reactive by ELISA, IFA and WB and induced ISI
>65%, and appeared to be associated with the adjuvant used, with
GLA-SE and Montanide performing better than Alum. However,
in terms of functional antibodies activity, no signiﬁcant difference
was observed among the three groups.
These results stress the complexity of adjuvants. While Alum is
most commonly used with human vaccines [42], it has not been
found successful against malaria since such vaccines induce Th2
responses that are poorly effective against malaria parasites where
protection is mainly mediated by Th1 responses. Here, one of the
mouse stains displayed a strong but variable antibody response
when the polypeptide was formulated in Alum. In general, in
this study PvCS-NRC formulated in adjuvants Montanide ISA51
and GLA-SE induced strong antibody responses in most mouse
strains tested. Immunogenicity of peptides formulated in Mon-
tanide ISA720 and ISA51 has been determined in previous studies
on CS-LSP in Aotus monkeys [22,24] and human volunteers [23,25].
These formulations have been shown to be safe, well tolerated and
immunogenic. However in other studies, Montanide formulations
have been reported to induce reactogenicity as well as stability
and reproducibility problems among different formulation batches
[43–45].
We proposed to use a Glucopyranosyl lipid A stable oil-in-water
emulsion (GLA-SE) previously shown to produce strong cellular
and/or humoral immune responses in animal models [26,33,34,46].
In the present study, GLA-SE formulations induced the strongest
humoral responses in both inbred and outbred mice, and anti-
bodies obtained from immunized mice appeared to induce the
strongest in vitro inhibition of sporozoite invasion, although no sig-
niﬁcant differences were observed regarding the formulation used.
The GLA-SE formulation also induced antibodies that recognized
all epitopes in the PvCS-NRC polypeptide, including reactivity with
the two repeat variants, and being the only groups of mice that
recognized VK247 variant.
Antibodies obtained by immunization with the polypeptide for-
mulated in all tested adjuvants recognized the native protein in
IFAT and Western blot regarding to the strain used. Three main
bands were observed, two bands at approximately 50 kDa  are typ-
ical of the CS protein [47], whereas the band at 15 kDa could
correspond to fragments of the processed CS protein.
This study conﬁrms that the use of synthetic peptides repre-
sents a promising strategy for vaccine development. LSPs with
lengths >100 amino acids can now be routinely and reproducibly
synthesized [48]. Since for liver stage antigens where elicitation
of a speciﬁc T-cell response is needed and linear peptides of lim-
ited length are required we  argue that short peptides containing
speciﬁc T-cell and B-cell epitopes inserted co-linearly into a long
peptide chain with interposed non-immunogenic spacers to min-
imize the neo-epitopes formation could be enough to induce a
protective immune response directed to the protein [37]. In conclu-
sion, given the encouraging results obtained in this study, further
studies are warranted for evaluation of PvCS-NRC as a potential
vaccine candidate.
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